Welcome to our book review site go-pdf.online!
You may have to Search all our reviewed books and magazines, click the sign up button below to create a free account.
Nanotechnology Applied To Pharmaceutical Technology
Focusing on the application of nanotechnology in pharmaceutical technology the editors seek to integrate the two in order to obtain innovative products and solutions in pharmacology. Interdisciplinary in content it is of interest to those who are involved in the development of nanoproducts including nanotechnologists, microbiologists, biotechnologists pharmacologists and clinicians. Recent studies are presented that include the biosynthesis of nanoparticles focusing on antimicrobials; nanomaterial-based formulations that treat cancer, infections, skin disorders and wounds;nanomaterials in eye diseases and toxicity and safety issues. It demonstrates the crucial role this plays in tackling multi-drug resistant threats.
Nanomaterials: Ecotoxicity, Safety, and Public Perception
The environment is prone to suffer pollution and toxic insult from generations of nanomaterials as well from accidental releases during production, transportation, and disposal operations. The NMs could interact with and cause adverse biological effects at cellular, subcellular, and molecular levels. Assessing potential environmental/ecological risks requires quality information on transport and fate of nanoparticles in the environment, exposures and vulnerabilities of organisms to the nanomaterials and standard methods for assessing toxicity for aquatic or terrestrial organisms and human health. The systematic risk characterization and evaluation of the safety of nanomaterials require a mul...
New Insights & Updates on The Molecular Epidemiology and Antimicrobial Resistance of MRSA in Humans in the Whole-Genome Sequencing Era
Methicillin-resistant Staphylococcus aureus (MRSA) have been a major cause of healthcare-associated (HA) infection globally for several decades. During this time many distinct clones have emerged independently around the world, some of which have achieved pandemic status. More recently, community-associated (CA) and livestock-associated MRSA clones have also emerged, some of which have become established in hospitals and other healthcare facilities, and sometimes have displaced previously predominant HA clones. Importantly, MRSA can frequently exhibit resistance to a wide range of clinically relevant antibiotics, which limits treatment options and complicates patient management and outcomes....
Surveying Antimicrobial Resistance: Approaches, Issues, and Challenges to Overcome
Why Antibiotic Resistance? The use of antibiotics in human and veterinary medicine may have consequences beyond their intended applications. The “One Health” concept recognizes that the health of humans is connected to the health of animals and the environment. Progress in molecular genetics is facilitating the rapid evaluation of the essentiality of these targets on a genomic scale. In 2015, a group of researchers established the International Conference on Antibiotic Resistance (IC2AR).The primary objective of this meeting is to bring together scientists involved in antibiotic resistance prevention and control. The IC2AR conducted its inaugural world congress in January 2015 at Caparic...
Advancements in Interdisciplinary Research
This volume constitutes selected and revised papers presented at the First International Conference on Advancements in Interdisciplinary Research, AIR 2022, held in Allahabad, India, in May 2022. The 49 papers were thoroughly reviewed and selected from the 252 submissions. They are organized in topical sections on novel technologies enabled secured privacy models and optimized networking infrastructures toward secure industries; developments towards sustainable healthcare sector; machine learning and deep learning enabled applications in different sectors; robotics and computer vision for intelligent automation in industries; trending technologies: frameworks and applications focusing real life issues.
Frontiers in Anti-Infective Drug Discovery: Volume 8
This book series brings updated reviews to readers interested in advances in the development of anti-infective drug design and discovery. The scope of the book series covers a range of topics including rational drug design and drug discovery, medicinal chemistry, in-silico drug design, combinatorial chemistry, high-throughput screening, drug targets, recent important patents, and structure-activity relationships. Frontiers in Anti-Infective Drug Discovery is a valuable resource for pharmaceutical scientists and post-graduate students seeking updated and critically important information for developing clinical trials and devising research plans in this field. The eighth volume of this series ...
Therapeutics for Ebola virus disease, 19 August 2022
Ebola virus disease (EVD) is a life-threatening disease caused by Ebola virus (EBOV; Zaire ebolavirus). Viruses of the genus Ebolavirus (of the family Filoviridae) can cause life-threatening disease. EBOV causes outbreaks of EVD, historically the most severe and most frequent. This guidance, due to the evidence available, is directed only to the treatment of EVD, the disease caused by EBOV (Zaire ebolavirus). During early EVD, patients present with a non-specific febrile illness, followed by gastrointestinal signs and symptoms that frequently lead to hypovolaemia, metabolic acidosis, hypoglycaemia, and multi-organ failure. EVD case fatality remains high, with a pooled case fatality rate of 60% (95% confidence interval [CI]: 47–73%) in outbreaks from 2010–2020. Following the publication of an RCT demonstrating superior efficacy of two EVD therapeutics, in comparison to the ZMapp control arm, WHO proposed to develop a new guideline. This is a new guideline written to accompany the optimized supportive care (oSoC) for EVD standard operating procedures. The guideline aims to summarize high quality evidence for EVD therapeutics and make recommendations for their use.
